IP Library Granted Patent US 9,629,789
Granted Patent B2
US 9,629,789 · App. 14/026,592 · Granted Apr 25, 2017

Rosacea treatments using polymetal complexes

Inventors: Joseph R. Faryniarz (Middlebury, CT); Jose E Ramirez (Trumbull, CT); Hovig Ounian (Denton, TX)
Assignee: Obagi Medical Products, Inc.
A61K8/67A61K8/27A61K8/362A61K8/671A61K31/07A61K31/235A61K31/315A61K31/415A61K31/4164A61K31/59A61K31/60A61K33/30A61K45/06A61Q17/04A61Q19/00A61Q19/10A61K2800/88A61K2800/884
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,629,789
App. No.
14/026,592
Granted
Apr 25, 2017
Kind
B2
Abstract

Described herein are novel methods for the treatment of rosacea which include the step of applying of a composition containing a polymetal complex to an area of the skin afflicted with rosacea and novel regimens using such compounds.

Claims (27)

1. A treatment regimen comprising:

an A.M. treatment regimen comprising the steps of: (1) cleansing an area of skin afflicted with rosacea with an antimicrobial or antibiotic cleanser; (2) applying to the cleansed area a moisturizing composition, wherein the moisturizing composition comprises a Cu/Zn malonate complex; (3) applying an anti-redness composition to the cleansed and Cu/Zn malonate-treated area; and (4) applying to the cleansed and Cu/Zn malonate-treated area a protective composition, wherein the protective composition comprises a sunscreen; and

a P.M. treatment regimen comprising the steps of (1) cleansing an area of skin afflicted with rosacea with an antimicrobial or antibiotic cleanser; (2) applying to the cleansed area a moisturizing composition, wherein the moisturizing composition comprises a Cu/Zn malonate complex, and (3) applying an anti-redness composition to the cleansed and Cu/Zn malonate-treated area; wherein the P.M. treatment regimen does not comprise applying a protective composition comprising a sunscreen.

2. The treatment regimen of claim 1 , wherein for either or both of the A.M. treatment regimen or the P.M. treatment regimen, prior to the step of applying the composition comprising the Cu/Zn malonate complex, the regimen further comprises applying a composition containing metronidazole to the cleansed area.

3. The treatment regimen of claim 1 , wherein in the A.M. treatment regimen subsequent to the step of applying the protective composition, the regimen further comprises applying an anti-parasitic compound to the cleansed, Cu/Zn malonate-treated, and protective composition-treated area.

4. The treatment regimen of claim 3 wherein the anti-parasitic product is selected from the group consisting of benzyl benzoate, salicylic acid and combinations thereof.

5. The treatment regimen of claim 1 , wherein the moisturizing composition comprises Cu/Zn malonate complex in an amount from about 0.001 to about 5% by weight of the total composition.

6. The treatment regimen of claim 1 wherein the protective composition comprises a compound selected from the group consisting of ZnO, Vitamin A, Vitamin D and combinations thereof.

7. The treatment regimen of claim 1 , wherein in the A.M. treatment regimen subsequent to the step of applying the protective composition, the regimen further comprises applying a benzoyl peroxide containing composition to the cleansed, Cu/Zn malonate-treated, and protective composition-treated area.

8. The treatment regimen as in claim 1 , wherein in the A.M. treatment regimen subsequent to the step of applying the protective composition, the regimen further comprises applying a retinoid containing composition to the cleansed, Cu/Zn malonate-treated, and protective composition-treated area.

9. The treatment regimen as in claim 1 , wherein in the A.M. treatment regimen subsequent to the step of applying the protective composition, the regimen further comprises applying an antibiotic containing composition to the cleansed, Cu/Zn malonate-treated, and protective composition-treated area.

10. The treatment regimen of claim 1 , wherein in the A.M. treatment regimen subsequent to the step of applying the protective composition, the regimen further comprises taking an oral antibiotic.

11. A kit comprising:

a first composition, wherein the first composition is a cleanser, wherein the cleanser comprises an antimicrobial or antibiotic compound;

a second composition, wherein the second composition is a moisturizing composition comprising a Cu/Zn malonate complex;

a third composition, wherein the third composition is a protective composition comprising a sunscreen;

a fourth composition, wherein the fourth composition is a composition containing metronidazole; and

a fifth composition, wherein the fifth composition is an anti-redness composition.

12. The kit of claim 11 further comprising a composition containing an anti-acne medication.

13. The kit of claim 11 further comprising an anti-parasitic composition.

14. The kit of claim 11 wherein the moisturizing composition comprises Cu/Zn malonate complex in an amount from about 0.001 to about 5% by weight of the total composition.

15. The kit of claim 11 wherein the protective composition comprises ZnO, vitamin A, vitamin D or combinations thereof in a dermatologically acceptable carrier.

16. The kit of claim 11 wherein the cleanser is an antimicrobial cleanser.

17. The kit of claim 16 wherein the antimicrobial cleanser is selected from the group consisting of chlorhexidine gluconate, triclosan, zinc pyrithione, clindamycin phosphate, sodium sulphacetamide and combinations thereof.

18. The kit of claim 11 wherein the anti-redness composition includes a compound selected from the group consisting of bisabolol, glycyrrhiza glabra root extract, sea whip extract, bacopa monniera extract, sodium cocoyl amino acids, lavandula angustifolia (lavender) flower/leaf stem extract, aloe barbadensis leaf juice, hydrolyzed oat protein, allantoin, avena sativa (oat) beta glucan, avena sativa (oat) kernel extract, arnica montana extract, cupressus sempervirens extract, polygontum multiflorum extract, sarcosine, potassium aspartate, magnesium aspartate, and combinations thereof, in a dermatologically acceptable carrier.

19. The kit of claim 12 wherein the anti-acne medication is selected from the group consisting of benzoyl peroxide, antibiotics, retinoids, and combinations thereof.

20. The kit of claim 13 wherein the anti-parasitic product includes a compound selected from the group consisting of benzyl benzoate, salicylic acid and combinations thereof.

Assignments (18)
SECURITY INTEREST Recorded Jul 30, 2026
From: OBAGI COSMECEUTICALS LLC
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 075464/0639 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0092 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0506 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 044750/0475 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OBAGI MEDICAL PRODUCTS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0718 →
SECURITY INTEREST Recorded Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; SOLTA MEDICAL, INC.; VALEANT CANADA LP, BY ITS GENERAL PARTNER VALEANT CANADA GP LIMITED; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT HOLDINGS IRELAND (AS SUCCESSOR TO VALEANT INTERNATIONAL BERMUDA); VALEANT PHARMACEUTICALS NORTH AMERICA LLC; VALEANT PHARMACEUTICALS IRELAND
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2014
From: JR CHEM, LLC
To: OBAGI MEDICAL PRODUCTS, INC.
Reel/Frame 033541/0153 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2014
From: FARYNIARZ, JOSEPH R.; RAMIREZ, JOSE E.; OUNANIAN, HOVIG
To: JR CHEM, LLC
Reel/Frame 033541/0108 →
Continuity (3)
Continuation 12831424 · Jul 7, 2010
Provisional Application 61225041 · Jul 13, 2009
Related Publication 20140134119A1 · May 15, 2014